Allakos Secures $100 Million In Series B Financing
Proceeds will support advancement of AK002 in five disease areas Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease SAN CARLOS, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Allakos Inc., a …